中华眼科杂志
中華眼科雜誌
중화안과잡지
Chinese Journal of Ophthalmology
2014年
10期
729-732
,共4页
顼晓琳%李彬%王怡琛%高飞%张志豹
頊曉琳%李彬%王怡琛%高飛%張誌豹
욱효림%리빈%왕이침%고비%장지표
视网膜母细胞瘤%肿瘤消退,自行性
視網膜母細胞瘤%腫瘤消退,自行性
시망막모세포류%종류소퇴,자행성
Retinoblastoma%Neoplasm regression,spontaneous
目的 分析视网膜母细胞瘤(RB)自发退行的临床表现和组织病理学特点.方法 回顾性系列病例研究.对北京同仁眼科中心病理室2007年1月至2013年12月间存档的579例因RB(术前未化疗)行眼球摘除的眼球标本中,表现为RB自发退行的52例的临床及组织病理学资料进行总结分析,主要分析了肿瘤细胞存活状况、肿瘤侵犯范围、葡萄膜和晶状体等眼内组织结构变化等情况.结果 52例RB患儿平均年龄为(14.0±8.7)个月,男性33例(63.5%),女性19例(36.5%).自发退行率为9.0%(52/579),其中完全自发退行率为1.4%(8/579).最常见的首发症状是白瞳征伴眼红29例(55.8%),多数最终表现为眼球萎缩或眼球痨.典型的组织病理学特征:(1)眼球内肿瘤细胞全部或绝大多数发生凝固性坏死,仅见残存的肿瘤细胞残骸.(2)多数眼球体积明显萎缩变小或为眼球痨改变.(3)葡萄膜高度萎缩,色素细胞崩解,组织结构紊乱,尤其以虹膜、睫状体最为显著.(4)白内障,晶状体膨胀、移位、纤维结缔组织膜包裹.(5)23.1% (12/52)的病例虽然眼球内的肿瘤组织已表现为典型的自发退行改变,然而,球后视神经内或脉络膜内仍可见有存活的肿瘤细胞,具有高危组织病理学因素,具有肿瘤向远处扩散、转移的风险.结论 应重视婴幼儿出现白瞳征伴眼红、眼球萎缩等不典型的临床表现,警惕RB自发退行的可能性;同时,对少数具有高危组织病理学因素的自发退行病例,术后应给予化学治疗等全身辅助治疗并密切随访观察.
目的 分析視網膜母細胞瘤(RB)自髮退行的臨床錶現和組織病理學特點.方法 迴顧性繫列病例研究.對北京同仁眼科中心病理室2007年1月至2013年12月間存檔的579例因RB(術前未化療)行眼毬摘除的眼毬標本中,錶現為RB自髮退行的52例的臨床及組織病理學資料進行總結分析,主要分析瞭腫瘤細胞存活狀況、腫瘤侵犯範圍、葡萄膜和晶狀體等眼內組織結構變化等情況.結果 52例RB患兒平均年齡為(14.0±8.7)箇月,男性33例(63.5%),女性19例(36.5%).自髮退行率為9.0%(52/579),其中完全自髮退行率為1.4%(8/579).最常見的首髮癥狀是白瞳徵伴眼紅29例(55.8%),多數最終錶現為眼毬萎縮或眼毬癆.典型的組織病理學特徵:(1)眼毬內腫瘤細胞全部或絕大多數髮生凝固性壞死,僅見殘存的腫瘤細胞殘骸.(2)多數眼毬體積明顯萎縮變小或為眼毬癆改變.(3)葡萄膜高度萎縮,色素細胞崩解,組織結構紊亂,尤其以虹膜、睫狀體最為顯著.(4)白內障,晶狀體膨脹、移位、纖維結締組織膜包裹.(5)23.1% (12/52)的病例雖然眼毬內的腫瘤組織已錶現為典型的自髮退行改變,然而,毬後視神經內或脈絡膜內仍可見有存活的腫瘤細胞,具有高危組織病理學因素,具有腫瘤嚮遠處擴散、轉移的風險.結論 應重視嬰幼兒齣現白瞳徵伴眼紅、眼毬萎縮等不典型的臨床錶現,警惕RB自髮退行的可能性;同時,對少數具有高危組織病理學因素的自髮退行病例,術後應給予化學治療等全身輔助治療併密切隨訪觀察.
목적 분석시망막모세포류(RB)자발퇴행적림상표현화조직병이학특점.방법 회고성계렬병례연구.대북경동인안과중심병리실2007년1월지2013년12월간존당적579례인RB(술전미화료)행안구적제적안구표본중,표현위RB자발퇴행적52례적림상급조직병이학자료진행총결분석,주요분석료종류세포존활상황、종류침범범위、포도막화정상체등안내조직결구변화등정황.결과 52례RB환인평균년령위(14.0±8.7)개월,남성33례(63.5%),녀성19례(36.5%).자발퇴행솔위9.0%(52/579),기중완전자발퇴행솔위1.4%(8/579).최상견적수발증상시백동정반안홍29례(55.8%),다수최종표현위안구위축혹안구로.전형적조직병이학특정:(1)안구내종류세포전부혹절대다수발생응고성배사,부견잔존적종류세포잔해.(2)다수안구체적명현위축변소혹위안구로개변.(3)포도막고도위축,색소세포붕해,조직결구문란,우기이홍막、첩상체최위현저.(4)백내장,정상체팽창、이위、섬유결체조직막포과.(5)23.1% (12/52)적병례수연안구내적종류조직이표현위전형적자발퇴행개변,연이,구후시신경내혹맥락막내잉가견유존활적종류세포,구유고위조직병이학인소,구유종류향원처확산、전이적풍험.결론 응중시영유인출현백동정반안홍、안구위축등불전형적림상표현,경척RB자발퇴행적가능성;동시,대소수구유고위조직병이학인소적자발퇴행병례,술후응급여화학치료등전신보조치료병밀절수방관찰.
Objective To analyze the clinicopathologic characteristics of retinoblastoma spontaneous regression.Methods Retrospective case series study.The clinic and pathologic data of 52 cases of retinoblastoma spontaneous regression were analyzed retrospectively.All the cases came from 579 cases of retinoblastoma (without pre-enucleation chemotherapy) archived in Ophthalmic Pathology Laboratory of Beijing Tongren Eye Centre from Jan.2007 to Dec.2013.The analyzed factors included tumor activity,tumor invasion,and tissue changes of uveal and lens.Results In this study,the patients' average age was (14.0 ± 8.7) months.There were 33 (63.5%) male and 19 (36.5%) female patients.The rate of retinoblastoma spontaneous regression was 9.0% (52/579),of which the rate of complete regression was 1.4% (8/579).The most common symptom was leucocoria coupled with red eye 55.8% (29/52).The typical clinicopathologic characteristics were as follows:(1) all or most of all tumor cells suffered coagulation necrosis and only tumor cell remains were left; (2)most eyeballs showed atrophiabulbi or phthisis bulbi; (3) severe atrophy occurred in uvea,especially in iris and ciliary body combined with pigment cells disintegrating; (4) cataract formed coupled with lens swelling,displacement,or wrapped by fibrous connective tissue; (5) in a small number of cases,there were alive tumor cells in the retrolaminar optic nerve or choroid in spite of most tumor cells had suffered regression,indicating the patients had histopathologic high risk factors and had the dispositions of tumor diffusion and metastasis.Conclusions Some untypical clinical manifestation such as leukocoria coupled with red eye or atrophia bulbi should be paid close attention.The possibility of retinoblastoma spontaneous regression should be considered.Meanwhile,some cases of retinoblastoma spontaneous regression with histopathologic high risk factors should be given post-enucleation systemic adjuvant chemotherapy combined with close observations and follow-ups.